Clinical trials: Cerebral Amyloid Angiopathy
Alzheimer Disease, Cerebral Amyloid Angiopathy
Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)
Until now there is no medical treatment and/or intervention that can slow, stop or reverse the underlying neurodegenerative of Alzheimer's disease (AD).
- Trial name
- (AU-ROOAD) (NCT03824197)
- Testing
- EVOO, OO
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Auburn University
Cerebral Amyloid Angiopathy
Antibiotics Against Amyloid Angiopathy
We will perform a randomized clinical trial with minocycline. Minocycline is an antibiotic of the tetracycline family and known to modulate inflammation, gelatinase activity and angiogenesis, which we know are central mechanisms…
- Trial name
- BATMAN (NCT05680389)
- Testing
- Minocycline
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Leiden University Medical Center
Cerebral Amyloid Angiopathy
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)
Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients.
- Trial name
- SENECA (NCT04204642)
- Testing
- CAA patients data collection
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage
Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy
The purpose of this study is to 1. Early identify patients based on clinical manifestation, imaging, gene and histology, explore diagnostic tools 2. get gene repertoire of Chinese 3.
- Trial name
- NCT02361411
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University Third Hospital
Cerebral Amyloid Angiopathy
Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence.
- Trial name
- CORELIA (NCT03464344)
- Testing
- neurological, neuropsychological and MRI evaluation
- Where
- 4 sites in France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Toulouse
Cerebral Amyloid Angiopathy
the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
Ischemic cardiovascular and cerebrovascular diseases are the main causes of death among people. Antiplatelet threrapy is very important for patients to prevent ischemic cardiovascular and cerebrovascular diseases.Ischemic…
- Trial name
- NCT04654026
- Testing
- Aspirin/Clopidogrel
- Volunteers
- 43 people
- Sponsor
- Shenzhen Second People's Hospital
Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage Lobar
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence.
- Trial name
- CARE-ICH (NCT07026994)
- Testing
- Colchicine 0.5mg
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- Huashan Hospital
Cerebral Amyloid Aβ Angiopathy
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy
Cerebral Aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive impairment.
- Trial name
- GENERALITY2 (NCT06864000)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA).
- Conditions
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
- Trial name
- HCCAA (NCT07716865)
- Testing
- NACA
- Where
- Iceland
- Volunteers
- 15 people
- Sponsor
- Arctic Therapeutics
Intracerebral Hemorrhage
Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage
To evaluate Pet AV-45 Amyloid imaging in the etiological diagnosis of primary non traumatic intracerebral hemorrhage (Cerebral Amyloid Angiopathy and hypertension related hemorrhage).We hypothesize that patients with lobar…
- Trial name
- COGHIC-AV45 (NCT01619709)
- Testing
- Pet AV-45
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Toulouse
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Enpowering Progression Risk of Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical…
- Trial name
- PRIORITY (NCT06960538)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy, Hypertensive Arteriopathy
Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy
White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA).
- Trial name
- PVWMH (NCT05486897)
- Testing
- None, pure observational study
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cerebral Amyloid Angiopathy, Subarachnoid Hemorrhage
Detailed Clinical and MRI Characteristics in Primary Non-traumatic Convexity Subarachnoid Haemorrhage Elderly Patients.
Transient focal neurological episode (TFNE) is the most frequent presenting symptom of convexity subarachnoid haemorrhage (cSAH) in elderly patients with non-traumatic cSAH with suspected, possible or probable cerebral amyloid…
- Trial name
- cSAH (NCT04825808)
- Testing
- usual care
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease
Prognosis of Cerebral Small Vessel Disease
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients…
- Conditions
- Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease, Cadasil, CAA - Cerebral Amyloid Angiopathy
- Trial name
- PRO-SVD (NCT05734378)
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.
The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA.
- Trial name
- DIETETICA (NCT06933212)
- Testing
- Mediterranean Diet with Extra Virgin Olive Oil, Mediterranean Diet with Walnuts, Low-Fat Control Diet
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage
MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
In this three-year proposal, we will explore the MRI-visible EPVS in CAA and investigate its pathophysiology using animal models.
- Trial name
- CAA (NCT04604587)
- Testing
- 1. amyloid PET；2. T807 PET
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Intracerebral Hemorrhage, Cerebral Amyloid Angiopathy
Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy
Aim of the SuSPect-CAA study is to prospectively evaluate the prognostic significance of cortical superficial siderosis in patients with suspected cerebral amyloid angiopathy with a primary focus on future stroke and mortality.
- Conditions
- Intracerebral Hemorrhage, Cerebral Amyloid Angiopathy, Ischemic Stroke
- Trial name
- SuSPect-CAA (NCT01856699)
- Where
- Germany
- Volunteers
- 302 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Intracerebral Hemorrhage Lobar, Cerebral Amyloid Angiopathy
Remote Ischemic Conditioning for Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage
Cerebral amyloid angiopathy-related intracerebral (CAAH) hemorrhage is second factor of primary intracerebral hemorrhage. However, no effective prevention and treatment strategies have been established.
- Trial name
- RIC-CAAH (NCT04757597)
- Testing
- Remote ischemic conditioning
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Capital Medical University
Cerebral Amyloid Angiopathy
Balance Eyesight and Muscle Tension in the Cervical Spine in Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is one form of disease of the small vessels of the brain and can cause frequent cerebral hemorrhages as well as other types of stroke.
- Trial name
- NCT05082194
- Testing
- balance with open and closed eyes
- Where
- Poland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Anna Olczak
Cerebral Amyloid Angiopathy
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA)…
- Trial name
- cAPPricorn-1 (NCT06393712)
- Testing
- ALN-APP
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 210 people
- Sponsor
- Alnylam Pharmaceuticals